At a glance
- Originator Nanjing Chang'ao Pharmaceutical
- Developer Guangzhou Yipinhong Pharmaceutical; Nanjing Chang'ao Pharmaceutical
- Class Antivirals; Furans; Purines
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-II for Hepatitis B in China (PO) (Nanjing Chang'ao Pharmaceutical website, October 2021)
- 26 Jul 2017 Chemical structure information added
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-B in China (PO, Capsule)